Industry calls for R&D tax breaks in Hungary to boost research

4 March 2019

The leading trade group for the Hungarian pharmaceutical industry has called on Hungary’s government to help prevent a decline in novel research taking place in the country.

The Association of Innovative Pharmaceutical Manufacturers (AIPM) says Hungary risks losing its “previously distinguished position within the regional and EU ranking for clinical research,” due to increasing competition and new EU regulations.

In the past four years, requests for the authorization of new clinical trials have decreased by 18%, and the number of approved trials has gone down from 337 in 2015, to 290 in 2018.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK